- Conditions
- Metastatic Lobular Breast Carcinoma
- Interventions
- [68Ga]Ga DOTA-5G
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,094
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
- Conditions
- Breast Cancer, Hot Flashes
- Interventions
- gabapentin, antidepressant
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 162
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Augusta, Georgia + 101 more
- Conditions
- Follicular Lymphoma, Lymphoma
- Interventions
- Mosunetuzumab, Zanubrutinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Washington D.C., District of Columbia • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- Livmoniplimab, Budigalimab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 21
- States / cities
- Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Belinostat, CHOP
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Athens, Georgia • Rochester, Minnesota + 5 more
- Conditions
- Seizures
- Interventions
- Midazolam
- Drug
- Lead sponsor
- U.S. Army Office of the Surgeon General
- Federal
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
- Interventions
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks
- Drug
- Lead sponsor
- BBB-Therapeutics B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Ovarian Cancer
- Interventions
- Liposomal Doxorubicin, Topotecan
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
- Conditions
- Safety Issues, Tolerability, Pharmacokinetics
- Interventions
- IPG7236
- Drug
- Lead sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Austin, Texas
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, ADT, Abiraterone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- VELCADE™
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
- Conditions
- Injection Site Irritation
- Interventions
- Ondansetron, Lidocaine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Prostate Cancer
- Interventions
- High Dose brachytherapy boost, External beam radiotherapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 12
- States / cities
- Burbank, California • Inglewood, California • Sacramento, California + 9 more
- Conditions
- Smoking
- Interventions
- Financial counseling, Nicotine Replacement Therapy Agent - Patches, Nicotine Replacement Therapy Agent - Lozenges, Nicotine Replacement Therapy Agent - Gum
- Other · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 602 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pleural Mesothelioma, Metastatic Pleural Effusions
- Interventions
- Adenoviral-mediated Interferon-beta, SCH 721015
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma, Glioblastoma Multiforme
- Interventions
- 5-day TMZ, 21-day TMZ, PEP-CMV: Component A, Tetanus-Diphtheria booster, Tetanus Pre-Conditioning, PEP-CMV: Component B
- Drug · Biological
- Lead sponsor
- Eric Thompson, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery, Milestone 3: Chemoradiotherapy (cXRT), Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery, Milestone 4: Chemoradiotherapy (cXRT), Milestone 5: Targeted chemotherapy after surgery, Milestone 5: Chemoradiotherapy (cXRT), Milestone 6: Gemcitabine after surgery, Milestone 6: Chemoradiotherapy (cXRT), Milestone 7: Chemoradiotherapy (cXRT), Milestone 8: Targeted chemotherapy after surgery, Milestone 9: Gemcitabine after surgery, Milestone 10: No additional therapy after surgery
- Drug · Radiation · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Milwaukee, Wisconsin
- Conditions
- Mucositis, Multiple Myeloma
- Interventions
- Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment
- Biological · Drug · Other + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
- Biological · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Interventions
- JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
- Biological · Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 9
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more